BridgeBio Pharma To Present Detailed Results From The Phase 3 ATTRibute Study In Patients With Transthyretin Amyloidosis Cardiomyopathy At European Society Of Cardiology Congress 2023
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that detailed Phase 3